Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of BZE2204 CD19/CD22/BCMA CAR-T Cells in Subjects With Relapsed or Refractory Active Autoimmune Diseases

NCT07174843 is registered in ClinicalTrials.gov with Shanghai Cell Therapy Group Co.,Ltd as lead sponsor.

NCT NCT07174843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07174843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of BZE2204 CD19/CD22/BCMA CAR-T Cells in Subjects With Relapsed or Refractory Active Autoimmune Diseases
Lead sponsor
Shanghai Cell Therapy Group Co.,Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2025
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies(iim), immune thrombocytopenia(itp), systemic lupus erythematosus(sle)